skip to content »

Department of Neurology

Houston, Texas

BCM neurologists see patients through the Baylor Clinic and some of the world's leading specialty clinics.
Department of Neurology
not shown on screen

Previous Clinical Trials

Cholinesterase Inhibitors

  • “A Double-Blind Placebo-Controlled Parallel-Group Multicenter Study of Tacrine (CI-970-61) with Doses up to 160 mg/day in Patients with Alzheimer’s Disease,” and Open-Label Extension Study, Parke-Davis, 1991-1995
  • “A Preliminary Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease,” and Open-Label Extension Study (201/202), Eisai America, 1991-1997
  • “A 15-Week Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease,” and Open-Label Extension Study (301/303), Eisai America, 1994-1998
  • “A 54-Week Randomized Double-Blind Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer’s Disease with a Staged Crossover to Open-Label Donepezil,” and Open-Label Extension Study (E2020-A001-312/314), Eisai America, 1996-1998
  • “An Open-Label Study to Evaluate the Safety and Efficacy of 1/5 mg b.i.d. (3mg/day) through 6 mg b.i.d. (12mg/day) Exelon in Patients with Probable Alzheimer’s Disease in the Community Setting”, Novartis, 1997-2000
  • “A 24-Week Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease” (E2020-A001-308/309), Eisai, 1998-2001
  • “A Single-Center Randomized Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of 15 and 20 mg Donepezil Hydrochloride in Patients with Mild to Moderate Alzheimer’s Disease Treated with Aricept 10 mg daily”, Pfizer/Eisai, 2001-2003
  • “The Efficacy of Controlled-Release Oral Physostigmine in Alzheimer’s Disease and Senile Dementia of the Alzheimer’s Type” Forest Laboratories, 1989-1992

Other Cholinergic Therapies

  • “A 12-Week Double-Blind Placebo-Controlled Parallel-Group Dose-Response Multicenter Study of CI-979 in Patients with Alzheimer’s Disease,” and Open-Label Extension Study, Parke-Davis, 1993-1996
  • “A Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of the Efficacy and Tolerability of SB202026 in Patients Suffering From Dementia of the Alzheimer’s Type,” and Open-Label Extension Study (007), SmithKlineBeecham, 1994-1998
  • “A 26-Week Randomized Double-Blind Placebo-Controlled Parallel-Group Mutlicenter Study of Milameline (C1979/RU35926) in Patients with Probable Alzheimer’s Disease,” and Open-Label Extension Study, Parke-Davis, 1996-1997
  • “A 24-Week Double-Blind Placebo-Controlled Parallel-Group Fixed-Dose Study of the Efficacy and Tolerability of SB202026 25ug b.i.d. and SB202026 50ug o.d. in Patients Suffering from Dementia of the Probable Alzheimer’s Type,” and Open-Label Extension Study (045/050), SmithKlineBeecham, 1996-1998
  • “Randomized Double-Blind Placebo-Controlled Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of LU-25-109 in Patients with Alzheimer’s Disease”, Lundbeck, 1997-1999.
  • “Efficacy and Safety of 6, 12, 24, and 36 mg t.i.d. po and 36 mg b.i.d. po Talsaclidine (free base) for 12 Weeks in a Double-Blind Randomized Placebo-Controlled Group Comparison in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”, Boehringer Ingelheim, 1999-2000
  • “Phase III 12-Week Randomized Double-Blind Placebo-Controlled Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457, 920 (30 mg q.d., 60 mg b.i.d., 120 mg b.i.d.) and Donepezil in Outpatients with Alzheimer’s Disease”, Pfizer, 2001-2003

Non-Cholinergic Therapies

  • “Alzheimer’s Disease Co-Operative Study Unit, Selegiline/Tocopherol Study” National Institute of Health (NIH), 1992-1994
  • “Alzheimer’s Disease Co-Operative Study Unit, Multicenter Evaluation of New Treatment Efficacy Measures”, National Institute of Health (NIH), 1993-1994
  • “A Controlled Study of Ondansetron in the Treatment of Primary Degenerative Dementia of the Alzheimer’s Type,” and Open-Label Extension Study, Glaxo Inc., 1993-1996
  • “Alzheimer’s Disease Co-Operative Study Unit, Estrogen Study” National Institute of Health (NIH), 1997-1999
  • “Alzheimer’s Disease Co-Operative Study Unit, Melatonin Study” National Institute of Health (NIH), 1997-1999
  • “Efficacy and Long-Term Tolerability of Memantine in Patients with Moderately Severe to Severe Alzheimer’s Disease (AD)”, Merz, 1998-1999
  • “Alzheimer’s Disease Co-Operative Study Unit, Mild Cognitive Impairment Study” National Institute of Health (NIH), 1998-2003
  • “A 24-Week Multicenter Parallel-Group Double-Blind Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Estrogen in the Treatment of Alzheimer’s Disease in Outpatients Treated with Donepezil”, Pfizer, 1999-2001
  • “Alzheimer’s Disease Co-Operative Study Unit, Rofecoxib/Naproxen Study” National Institute of Health (NIH), 2000-2002
  • “A Randomized Double-Blind Safety, Tolerability, Immunogenicity, and Pilot Efficacy Study of AN 1792 (QS-21) in Patients with Mild to Moderate Alzheimer’s Disease”, Elan, 2001-2003
  • “A Randomized Double-Blind Placebo Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”, Forest labs, 2002-2003